cord blood-derived allogeneic hematopoietic stem cell therapy (SynBio/Human Stem Cell Institute)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namecord blood-derived allogeneic hematopoietic stem cell therapy (SynBio/Human Stem Cell Institute)

Drug Alias NameGemacellSYN-20092304RU

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyBiologics > Blood componentsCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapy

Mechanisms of ActionHaematopoiesis stimulantsStem cells stimulants

TargetsUpdating

Therapy Area/IndicationsMyocardial InfarctionLiver Cirrhosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesHuman Stem Cells Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHuman Stem Cells Institute Synbio

Active IndicationsN/A

Inactive IndicationsMyocardial InfarctionLiver Cirrhosis

Other Information

ATC CodeN/A